Poor Glycemic Control Affecting Screening of Prostate Carcinoma

Area of Science:

• Endocrinology
• Oncology
• Clinical Biochemistry

Background:

• Diabetes mellitus is linked to cancer progression through factors like insulin resistance and chronic inflammation.
• Prostate-specific antigen (PSA) is a biomarker for prostate cancer, influenced by age, benign prostatic hyperplasia, prostatitis, and BMI.
• While diabetes can increase malignancy risk, it may reduce prostate cancer risk due to lower testosterone levels and metformin's association with lower PSA.

Purpose of the Study:

• To evaluate serum PSA levels in diabetic patients with poor glycemic control (HbA1c ≥ 7%) versus good glycemic control (HbA1c < 7%).

Main Methods:

• An observational study included 318 diabetic patients from Indira Gandhi Institute of Medical Sciences, Patna.
• Serum PSA, fasting plasma glucose (FPG), and HbA1c levels were measured using chemiluminescent immunoassay, hexokinase method, and chromatography, respectively.
• Statistical analyses, including Mann-Whitney U test and covariance analysis, were performed using SPSS software.

Main Results:

• Serum PSA levels were significantly lower in patients with poor glycemic control (median 0.49) compared to those with good glycemic control (median 0.99).
• This significant difference was also observed in the subgroup with PSA values < 4 ng/ml.
• No significant differences in PSA levels were found in subgroups with PSA values between 4-8 ng/ml and > 8 ng/ml.

Conclusions:

• Diabetic patients with poor glycemic control exhibit lower serum PSA levels than those with good glycemic control.
• Further research with larger sample sizes and detailed diabetes history is recommended to confirm these findings.